{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Valiant Organics Ltd
Valiant Organics Hits Upper Circuit Amid Strong Buying Pressure
Valiant Organics Ltd witnessed robust buying interest on 4 December 2025, with its stock price hitting the upper circuit limit of ₹268.10, marking a maximum daily gain of 4.99%. This surge outpaced the Specialty Chemicals sector and broader market indices, reflecting heightened investor enthusiasm despite a recent period of subdued activity.
Valiant Organics Surges with Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit
Valiant Organics Ltd has witnessed extraordinary buying momentum today, registering a 5.00% gain and hitting an intraday high of Rs 268.85. The stock’s performance stands in stark contrast to the broader market, with the Sensex advancing a modest 0.23%, underscoring a rare scenario where only buy orders populate the order book, signalling potential for a sustained multi-day upper circuit.
Valiant Organics Technical Momentum Shifts Amid Market Challenges
Valiant Organics, a key player in the Specialty Chemicals sector, has experienced notable shifts in its technical momentum as recent market assessments reveal a transition from bearish to mildly bearish trends. This article analyses the evolving technical indicators, price movements, and comparative returns to provide a comprehensive view of the stock’s current positioning.
Valiant Organics Hits Upper Circuit Amid Strong Buying Pressure
Valiant Organics Ltd, a micro-cap player in the specialty chemicals sector, witnessed robust buying interest on 1 Dec 2025, hitting its upper circuit limit with a 5.0% gain to close at ₹264.80. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm despite a backdrop of subdued delivery volumes and mixed moving average signals.
Valiant Organics Sees Revision in Market Evaluation Amid Specialty Chemicals Sector Challenges
Valiant Organics, a microcap player in the Specialty Chemicals sector, has experienced a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, signalling a more cautious stance on its near-term prospects.
Valiant Organics Hits Lower Circuit Amid Heavy Selling Pressure
Valiant Organics Ltd, a micro-cap player in the Specialty Chemicals sector, witnessed a sharp decline on 20 Nov 2025 as its stock hit the lower circuit price limit, reflecting intense selling pressure and a significant intraday loss. The stock’s performance underperformed its sector peers and broader market indices, signalling a period of heightened volatility and investor caution.
Is Valiant Organics overvalued or undervalued?
As of November 17, 2025, Valiant Organics is considered overvalued with a valuation grade of "attractive," reflected by a PE ratio of 33.75, lower ROCE and ROE compared to peers, and a year-to-date return of -7.03%, lagging behind the Sensex's 8.72%.
Valiant Organics Q2 FY26: Profit Recovery Masks Underlying Revenue Weakness
Valiant Organics Ltd., a specialty chemicals manufacturer focused on agro intermediates and pharma applications, reported a consolidated net profit of ₹5.67 crores for Q2 FY26, marking a sharp turnaround from the ₹12.78 crore loss recorded in the same quarter last year. However, the recovery came amidst a concerning 23.04% sequential revenue decline, raising questions about the sustainability of the company's operational momentum. The stock, trading at ₹285.90 with a market capitalisation of ₹807.00 crores, has declined 19.97% over the past year, significantly underperforming both the Sensex and its specialty chemicals peer group.
How has been the historical performance of Valiant Organics?
Valiant Organics has faced significant fluctuations in financial performance, with net sales declining from 1,051.80 Cr in March 2023 to 718.76 Cr in March 2025, while profitability metrics have also decreased, resulting in a negative profit after tax of -2.67 Cr in March 2025. Despite a slight recovery in operating profit, the overall financial environment remains challenging.
How has been the historical performance of Valiant Organics?
Valiant Organics has faced significant financial challenges, with net sales dropping from 1,153.27 Cr in Mar'22 to 718.76 Cr in Mar'25, and operating profit declining from 212.27 Cr to 62.31 Cr in the same period. The company reported losses in profit after tax for the last two years, indicating a difficult performance trajectory.
Valiant Organics Faces Significant Selling Pressure with 16.08% Loss Over Three Months
Valiant Organics Ltd is experiencing significant selling pressure, continuing a trend of losses and underperformance against the broader market. The stock has declined over various time frames, including a notable 53.46% drop over three years, and is currently trading below multiple moving averages, indicating ongoing challenges.
When is the next results date for Valiant Organics?
Valiant Organics will declare its results on 13 November 2025.
Why is Valiant Organics falling/rising?
As of 10-Nov, Valiant Organics Ltd's stock price is Rs 290.15, down 2.75% and has declined 4.87% over the last four days. The stock is underperforming compared to its sector and the Sensex, with a year-to-date drop of 4.87% against a 6.91% gain in the benchmark.
Valiant Organics Faces Significant Selling Pressure with Yearly Loss of 24.12% Amid Declines
Valiant Organics Ltd is experiencing significant selling pressure, continuing a trend of losses with a 2.38% decline over the past week and a 9.05% drop in the last month. The stock has underperformed the Sensex, with a 24.12% decrease over the past year and substantial declines over longer periods.
How has been the historical performance of Valiant Organics?
Valiant Organics has shown a declining trend in financial performance, with net sales dropping from INR 1,153.27 crore in March 2022 to INR 718.76 crore in March 2025, and net profit turning negative from INR 113.28 crore to a loss of INR 3.74 crore in the same period. Operating cash flow also significantly decreased, indicating challenges in core operations.
Is Valiant Organics overvalued or undervalued?
As of October 29, 2025, Valiant Organics is considered overvalued with a PE ratio of 170.26 and an EV to EBITDA of 17.61, making it less favorable compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 1.26% against the Sensex's 8.78%.
Is Valiant Organics overvalued or undervalued?
As of October 28, 2025, Valiant Organics is considered overvalued with a high PE ratio of 173.65 and a decline of 20.33% in stock price over the past year, contrasting with the positive performance of its peers and the Sensex.
How has been the historical performance of Valiant Organics?
Valiant Organics has faced significant financial challenges, with net sales declining from 1,153.27 Cr in Mar'22 to 718.76 Cr in Mar'25, and profit after tax dropping from 127.91 Cr to a loss of 3.74 Cr in the same period. Key metrics such as operating profit and cash flow from operating activities also decreased markedly.
Why is Valiant Organics falling/rising?
As of 23-Oct, Valiant Organics Ltd is currently priced at Rs 312.00, reflecting a short-term gain but a longer-term decline of 24.96% over the past year. Despite outperforming the Sensex in the short term, the stock's overall performance has been mixed, raising concerns about sustained investor interest.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
